“And when you exclude the impact of the headwind of China's GARDASIL, we have underlying growth of between 6% and 8%.”

In context

“usiness that we need to be aware about. Peter Dannenbaum: Your line cut out. I think the question was about the -- you see a reduction in the guidance, but can you talk about guidance, Caroline? Caroline A. Litchfield: Sure. So the guidance that we've given this quarter is to maintain the midpoint for revenues and to increase EPS by $0.03. There was a very modest tailwind from foreign exchange, and that has really offset a few headwinds. The first would be a low level of COVID cases during the summer season, which has impacted our outlook for LAGEVRIO. The second is we have seen an early entrant of a biosimilar for pembrolizumab in Argentina, which has impacted revenues there. All of that said, we are confident in our ability to drive growth in our business this year of between 1% and 2%. And when you exclude the impact of the headwind of China's GARDASIL, we have underlying growth of between 6% and 8%. So we're confident in our future despite the uncertain macro environment that does exist for our industry. Peter Dannenbaum: Great. Thank you all very much for your questions. As always, Investor Relations is available for any follow-ups. Thank you very much. Robert M. Davis: Thank you. Operator: Thank you. This concludes today's conference. We thank you for your participation. At this time, you may disconnect your lines.”